In order to improve distribution effectiveness, quality of care, data collection, and other health information, specialty pharmacies and healthcare groups need to focus on expanding their patient and treatment management services. Building key collaborations with third party health care groups that […]
How Can You Leverage Specialty Pharmacy in ACOs?
Join Armada Health Care as they host a complimentary webinar series addressing this topic. This 4-part webinar series includes a live forum at the upcoming 10th Annual Specialty Pharmacy Summit & Expo in Las Vegas. […]
Read the Latest Issue of Avella’s Dispensing Excellence
In the latest issue of Avella's publication, Dispensing Excellence, you will find topics ranging from the path of a specialty prescription, hepatitis specialty pharmacy selection tips, and a 2013 oncology medication review. Read the latest issue here. (Source: Avella, 1/2014) […]
CEA or MCDA – Which Will It Be?
AN ISPOR 16th Annual European Congress - Dublin session - Should Multi-Criteria Decision Analysis (MCDA) Replace Cost Effectiveness Analysis (CER) For Evaluation Of Health Care Coverage Decisions? Click the links below to see individual presentations. (Source: ISPOR 2013). Should MCDA Replace CEA […]
ISPOR Presents – The Many Perspectives on HTA
AN ISPOR 16th Annual European Congress - Dublin session - Early Engagement Between Manufacturers, HTA Assessors, and Regulators. Click the links below to see individual presentations. (Source: ISPOR 2013). Learning from the Past to Guide the Future The EMA Perspective NICE Scientific Advice: An […]
ISPOR Takes On Cystic Fibrosis
AN ISPOR 16th Annual European Congress - Dublin session - The Patient And Health Technology Assessment: Challenges And Opportunities. Click the links below to see individual presentations. (Source: ISPOR 2013). Evidence Supporting Reimbursement for a New Cystic Fibrosis Drug Health Technology […]
Study Finds Inconsistent Use Of Cost-Effectiveness Thresholds
This study looks at fundamental differences between the NHS and the Scottish Medicines Consortium (SMC), raising important policy issues - particularly in regards to the use of QALY thresholds - and then summarizes options in approaching this. Read more here. (Source: OHE, 12/12/13). […]
How To Run Successful Trials in Emerging Regions
The clinical development world is shrinking and running trials in emerging regions is becoming increasingly desirable and acceptable. This webinar, jointly presented by Pharm-Olam and ERT, will address the challenges most commonly faced by sponsor companies: managing patients, investigative sites, […]
ISPOR PRESIDENTIAL WELCOME
In his 2013-2014 Presidential Welcome William Crown, PhD, explains to ISPOR 16th Annual European Congress attendees how ISPOR is making an impact on health care decision making through our tools, best practices, and geographic diversity. Watch video here. (Source: ISPOR, 2013). […]
How To Use PRO To Compare Providers Fairly
In this article, the authors develop a method of adjusting for case mix that is intended to distinguish when variations in PROMs are the result of variations in the characteristics of patients, rather than variations in treatment success. Learn more here. (Source: OHE, 12/10/13). […]
Have You Checked Out ISPOR Distance Learning Program?
This module provides a general view of simple regression analysis with an explanation of why a standard simple approach fails in the estimation of medical costs. Furthermore, an overview of quantitative methods for modeling health care costs will be presented, including propensity score matching, […]
Who Said Pharmaceutical Market Access Was Easy?
Pharmaceutical market access is anything BUT easy! Just as you think you understand the rules of the game, they change. Value based pricing anyone? It is perhaps no surprise that the service community is rising to the challenge and offering a range of solutions to help organisations get their […]
Three Vital Areas for Improving Market Access – for Industry & Payer
Last year’s Pharma Pricing & Market Access Europe included discussions on key topics including: maneuvering changes in the healthcare environment, pricing & market access in the major international markets, and patient access and flexible pricing schemes. One particularly notable […]
The Moral Issues Behind Clinical Trials
As the cost of clinical trials continues to increase, pharmaceutical companies have chosen only those drugs in which they feel very confident on bringing a return. Often, leaving potentially life saving drugs on the self. How do we get more of these drugs to market at a reduced cost and risk to […]
How Can PROs Work For You?
The use of Patient-reported Outcomes is on the rise, and most companies are giving their PRO departments a little extra attention this coming year. Download this presentation given at Evidence 2013, by Ingela Wiklund, UBC, and learn How to Support Product Value Through Patient-reported Outcomes. […]
Value Based Pricing For Service Level Agreements: The Finale!
Check out Cicalini's Blog For the conclusion of this 3 part, 1 year case study. Read about the new sales and pricing organization, a change in management support, the implementation of a Sales and Pricing Master Class and of course the achievements thus far. (Source: Fabio Cicalini, Pricing2B, […]
Utilization Management Of Echocardiography – How Does It Affect Use Across Risk Groups
This study, conducted by outcomes research company, HealthCore, for AIM Specialty Health, evaluated the impact of an outpatient echocardiography utilization management (UM) program relative to a matched control (non-UM) group by measuring changes in utilization rates overall and within specific […]
How Much Do You Really Know About Big Data?
Analytics platforms and new healthcare-specific solutions together are offering far greater insight and intelligence into how healthcare providers are managing patient care, cost, and outcomes. Available as a podcast, on iTunes, full transcript or download here. (Source: ZDNet, 12/12/13). […]
2013 – Digital Blooms And More
Spotlight: Pharmacy in the UK, plus: The IQWIG on comparing medicines, Multi-channel marketing in China, online market research communities, Canada's oncology market, Digital intelligence, R&D pipeline, an innovation update and more…..Read the December issue of PME now. (Source: PMLiVE, December […]
University of Birmingham – What’s New In HEU?
The newsletter provides an overview of the current research and teaching activities in the HE Unit. Join in congratulating graduating students, welcoming new students, and read more on student projects and papers here. (Source: University of Birmingham HEU news, Winter 2013). […]
Bibliography of Major HEOR Publications, by IMS
IMS Real World Evidence group has released a bibliography of hundreds of relevant publications in the areas spanning major therapeutic areas (CV, Oncology, Asthma, diabetes, etc.) as well health policy, compliance, and more. Great reference source. (Source: IMS Health, 2013). […]
Will The Growing Need For Outcome Studies Lead To Higher Drug Costs?
It used to be that drugs were approved on the basis of their impact on markers of disease, however, over the last decade, long term studies measuring the effect of drugs on ultimate disease outcomes have yielded surprisingly unexpected results. As a result, no longer do you only need to convince […]
Who’s Leading PCORI’s Improving Healthcare Systems Program?
The Patient-Centered Outcomes Research Institute has tapped Steven Clauser of the National Cancer Institute to serve as director of its Improving Healthcare Systems Program.Clauser will succeed Dr. Chad Boult, who held the post since October 2012. PCORI, a Washington-based not-for-profit, […]
What Does Healthcare Look Like In 2014?
From an early surge in Medicare accountable care collaborations to the problematic rollout of the nation's historic health insurance exchanges during a 16-day government shutdown, healthcare in 2013 has been nothing short of unpredictable. Healthcare Trends & Forecasts in 2014: […]
FDA Adverse Event Reporting System – Why Is It Still Inaccessible
The centralized computerized information database for post-marketing drug safety surveillance is the FDA Adverse Event Reporting System (FAERS). Unfortunately, FAERS has remained inaccessible to healthcare professionals. In fact, publicly available FAERS information can only be obtained through […]
Mental Health – Call For Abstracts – Don’t Miss This Deadline!
DIAGNOSIS, PREVENTION AND TREATMENT IN MENTAL HEALTH: EFFECTIVENESS AND COMPARATIVE EFFECTIVENESS is the second meeting on patient reported outcomes and person centered care in mental health. The meeting will be held September 26-28 2014, in Washington DC. The deadline for abstract submission is […]
Do You Have a Nomination For The Steven G. Avey Award? Don’t Miss The Deadline!!
This award recognizes individuals for their distinguished contributions to managed care pharmacy, learn more about the Steven G. Avey Award here. It will be presented at the Annual Awards Dinner held during AMCP's 26th Annual Meeting & Expo in Tampa, Fl., April 1-4, 2014.(Source: AMCP […]
Have You Heard – Deep Is The New Big?
This presentation on Data & Analytics: Deep is the New Big; is given by Brian Sweet, Executive Director, AstraZeneca. He discusses why real world evidence is becoming increasingly important for pharma development, major challenges being faced and how they are being tackled, and a detailed case […]
Did You Hear Katie Murphy Light Up The First Plenary Session Of ISPOR Dublin?
Katie Murphy told over 3,000 audience members about her personal story in the fight against cystic fibrosis (CF), at the first plenary session of the 16th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Congress in Dublin. Afterwards she spoke with Pin Lu, from Rx […]
How Much Do You Know About Defensive Pricing?
Defensive pricing is a popular strategy used by pharmaceutical companies to counter threats from low-priced generic alternatives. This whitepaper explores how pricing can effectively support brands facing generic competition. Download here. (Source: Cutting Edge Information, 2013). […]
